EMBP1: The Embigin Pseudogene 1 (G647121)

Target Name: EMBP1

NCBI ID: G647121

EMBP1

Other Name(s): embigin pseudogene 1 | Embigin pseudogene 1

EMBP1: The Embigin Pseudogene 1

EMBP1 (embigin pseudogene 1) is a gene that encodes a protein known as embigin, which is a key regulator of the blood clotting system.EMBP1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

The Blood Clotting System

The blood clotting system is a complex process that helps to prevent blood from bleeding by forming a secure seal at the site of a blood vessel injury. This system is made up of various proteins, including EMBP1, which is involved in the regulation of the clotting factors that help to form this seal.

EMBP1 and Cancer

Studies have suggested that EMBP1 may be involved in the development and progression of cancer. For example, researchers have found that high levels of EMBP1 are associated with poor prognosis in patients with pancreatic cancer. Additionally, EMBP1 has been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer.

EMBP1 and Neurodegenerative Disorders

EMBP1 has also been linked to the development and progression of neurodegenerative disorders. For example, studies have shown that individuals with certain forms of neurodegenerative disorder, such as Alzheimer's disease, have higher levels of EMBP1 than those without the disorder. Additionally, research has suggested that EMBP1 may be a potential drug target for neurodegenerative disorders.

EMBP1 and Cardiovascular Diseases

EMBP1 has also been associated with the development and progression of cardiovascular diseases. For example, studies have shown that individuals with heart failure have higher levels of EMBP1 than those without the condition. Additionally, research has suggested that EMBP1 may be a potential drug target for cardiovascular diseases.

Drug Targets and Biomarkers

As a result of its involvement in the blood clotting system, EMBP1 has potential as a drug target for various diseases. For example, studies have shown that EMBP1 may be a potential target for cancer, neurodegenerative disorders, and cardiovascular diseases. Additionally, EMBP1 has been shown to be a potential biomarker for these conditions.

Conclusion

EMBP1 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Further research is needed to fully understand the role of EMBP1 in these conditions and to develop effective treatments.

Protein Name: Embigin Pseudogene 1

The "EMBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets